Clinical Trial Update: 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 imaging trial evaluating 89Zr-DFO-Atezolizumab with PET/CT in locally advanced or metastatic renal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)

Snippet

Sponsor: James Brugarolas | Conditions: Renal Cell Carcinoma | Phase 2 | Status: RECRUITING